Compare Abeona Therapeutics Inc (ABEO) vs Arqit Quantum Inc (ARQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Arqit Quantum Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Arqit Quantum Inc trades at $19.54 (market cap $345.44M). The key difference: Abeona Therapeutics Inc and Arqit Quantum Inc are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ARQQ | |
|---|---|---|
Market Cap | $373.32M | $345.44M |
Sector | Health | Technology |
52-Week High | $7.23 | $58.27 |
52-Week Low | $4.17 | $11.78 |
Enterprise Value | $228.22M | $318.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ARQQ trades at $22.13, down 5.89% today, with a bullish technical signal supported by moving averages. The company reported $530K revenue for 2025 but significant losses of -$35.34M net income, with negative margins and high P/S ratio of 319.93. Recent news highlights quantum security contract wins and 829% YoY revenue growth in H1 FY26, suggesting potential turnaround momentum despite current financial challenges.
Outlook remains speculative with high execution risk; substantial revenue growth and government/telecom deals offer upside, but persistent losses and negative ROE (-181%) pose significant shareholder value concerns. Analyst consensus is divided with 50% buy rating, indicating cautious optimism amid financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →
